Q2 2017 13F Holders as of 30 Jun 2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
108,074,661
-
Total 13F shares
-
25,609,895
-
Share change
-
+1,898,817
-
Total reported value
-
$694,432,125
-
Price per share
-
$27.12
-
Number of holders
-
101
-
Value change
-
+$43,716,393
-
Number of buys
-
72
-
Number of sells
-
48
Institutional Holders of Aclaris Therapeutics, Inc. - Common Stock (ACRS) as of Q2 2017
As of 30 Jun 2017,
Aclaris Therapeutics, Inc. - Common Stock (ACRS) was held by
101 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
25,609,895 shares.
The largest 10 holders included
Vivo Capital, LLC, FRANKLIN RESOURCES INC, FMR LLC, Sofinnova Management VIII, L.L.C., EAGLE ASSET MANAGEMENT INC, Polar Capital LLP, WESTFIELD CAPITAL MANAGEMENT CO LP, BlackRock Inc., Marshall Wace North America L.P., and Point72 Asset Management, L.P..
This page lists
101
institutional shareholders reporting positions in this security
for the Q2 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.